Adjuvanted pandemic influenza vaccine: Variation of emulsion components affects stability, antigen structure, and vaccine efficacy

Influenza and other Respiratory Viruses

Volumn 7, Issue 5, 2013, Pages 815-826

  Fox, Christopher B ^a   Barnes V, Lucien ^a   Evers, Tara ^a   Chesko, James D ^a   Vedvick, Thomas S ^a   Coler, Rhea N ^a   Reed, Steven G ^a   Baldwin, Susan L ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Oil in water emulsion; Pandemic influenza; Vaccine adjuvant

Indexed keywords

ALPHA TOCOPHEROL; AMMONIUM DERIVATIVE; AMMONIUM PHOSPHATE; EXCIPIENT; GLYCEROL; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2C ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; MIGLYOL; OIL; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; RECOMBINANT ANTIGEN; SORBITAN TRIOLEATE; SQUALENE; SURFACTANT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; WATER OIL CREAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; ELECTRON MICROSCOPY; EXPERIMENTAL MODEL; FEMALE; FLUORESCENCE SPECTROSCOPY; HEMAGGLUTINATION INHIBITION; HEMOLYSIS; IN VIVO STUDY; LIGHT SCATTERING; LIPID COMPOSITION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PARTICLE SIZE; PH; PLASMA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESSURE; PRIORITY JOURNAL; VISCOSITY; ZETA POTENTIAL;

OIL-IN-WATER EMULSION; PANDEMIC INFLUENZA; VACCINE ADJUVANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; EMULSIONS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED C57BL; PANDEMICS; VISCOSITY;

EID: 84882720512     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12031     Document Type: Article

References (22)

1. Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009; 14:3286-312.
2. Yang YW, Wu CA, Morrow WJW. Cell death induced by vaccine adjuvants containing surfactants. Vaccine 2004; 22:1524-36.
3. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011; 29:9563-72.
4. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. AAPS Pharm Sci Tech 2012; 13:498-506.
5. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998; 221:35-41.
6. Hibbert DB, Gooding JJ. Data Analysis for Chemistry. New York: Oxford University Press, 2006.
7. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21:201-30.
8. U.S. Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products [database on the Internet]. U.S. Food and Drug Administration. Available at http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (Accessed August 8, 2012).
9. Baldwin SL, Shaverdian N, Goto Y et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009; 27:5956-63.
10. Lousada-Dietrich S, Jogdand PS, Jepsen S et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011; 29:3284-92.
11. Massey JB, Pownall HJ. Interaction of α-tocopherol with model human high-density lipoproteins. Biophys J 1998; 75:2923-31.
12. Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick T. Monitoring the effects of component structure and source and formulation stability and adjuvant activity of oil-in-water emulsions. Coll Surf B: Bioint 2008; 65:98-105.
13. Yang YW, Wei AC, Shen SS. The immunogenicity-enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate--a revisit of the role of the hydrophile-lipophile balance (HLB) value. Vaccine 2005; 23:2665-75.
14. Relas H, Gylling H, Miettinen TA. Fate of intravenously administered squalene and plant sterols in human subjects. J Lipid Res 2001; 42:988-94.
15. Ball MJ. Hematological and biochemical effects of parenteral nutrition with medium chain triglycerides: comparison with long-chain triglycerides. Am J Clin Nutr 1991; 53:916-22.
16. Rossi J, Leroux JC. Principles in the development of intravenous lipid emulsions; in Wasan KM (ed.): Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery. Hoboken, NJ: John Wiley & Sons Inc., 2006; 88-123.
17. Yeh SL, Chao CY, Lin MT, Chen WJ. Effects of parenteral infusion with medium-chain triglycerides and safflower oil emulsions on hepatic lipids, plasma amino acids and inflammatory mediators in septic rats. Clin Nutr 2000; 19:115-20.
18. Sasol. Miglyol Product Information. Available at http://www.sasoltechdata.com/tds/miglyols.pdf (Accessed 17 December 2007).
19. Available at http://www.chemspider.com (Accessed 8 August 2012).
20. Jansen T, Hofmans MPM, Theelen MJG, Manders F, Schijns VEJC. Structure- and oil type-based efficacy of emulsion adjuvants. Vaccine 2006; 24:5400-5.
21. Jansen T, Hofmans MPM, Theelen MJG, Schijns VEJC. Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine 2005; 23:1053-60.
22. Morel S, Diderlaurent A, Bourguignon P et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73.